emphigus vulgaris is a rare autoimmune disease characterized by skin and mucous membrane blisters and erosions due to autoantibodies targeting desmogleins 1 and 3, which are major components of desmosomes. The severity of the disease can be assessed by measures such as the Harman score 1 or by newer scales, such as the Pemphigus Dis- However, to our knowledge, even though rituximab is considered a major promising treatment of pemphigus vulgaris, its efficacy in first-line treatment without systemic corticosteroids has not been assessed. We report herein a series of 5 patients who received successful treatment with a combination of rituximab and highly potent topical corticosteroids as first-line therapy.
First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids
Saskia Ingen-Housz-Oro, MD; Laurence Valeyrie-Allanore, MD; Anne Cosnes, MD; Nicolas Ortonne, MD, PhD; Sophie Hüe, MD, PhD; Muriel Paul, PhD; Pierre Wolkenstein, MD, PhD; Olivier Chosidow, MD, PhD P emphigus vulgaris is a rare autoimmune disease characterized by skin and mucous membrane blisters and erosions due to autoantibodies targeting desmogleins 1 and 3, which are major components of desmosomes. The severity of the disease can be assessed by measures such as the Harman score 1 or by newer scales, such as the Pemphigus Disease Area Index (PDAI) or Autoimmune Bullous Skin Disorder Intensity Score. 2 To date, except in cases with very limited lesions that can be treated by topical corticosteroid monotherapy, first-line treatment is based on high-dose systemic corticosteroids (1.0 or 1.5 mg/kg/d) according to the severity of the disease, 1, 3 but this treatment is complicated by a high rate of severe adverse effects, such as infections, osteoporosis, myopathy, and diabetes mellitus. Thus, adjuvant immunosuppressive therapies including corticosteroid-sparing agents are often warranted. A single cycle of rituximab has shown 4-6 excellent effectiveness in patients with refractory pemphigus vulgaris, as demonstrated by a greater than 80% rate of short-term complete remission, a dramatic corticosteroid-sparing action, and few severe adverse effects. The mechanism of action of rituximab in pemphigus vulgaris is based on prolonged inhibition of specific antidesmoglein B-cell response. However, to our knowledge, even though rituximab is considered a major promising treatment of pemphigus vulgaris, its efficacy in first-line treatment without systemic corticosteroids has not been assessed. We report herein a series of 5 patients who received successful treatment with a combination of rituximab and highly potent topical corticosteroids as first-line therapy.
Report of Cases
Five women in their 50s, 60s, or 70s had pemphigus vulgaris with PDAI scores ranging from 15 to 84 (highest possible score, 250) at diagnosis. The patients' clinical and immunologic characteristics are summarized in the Table. Because of various con-Premedication included a single infusion of methylprednisolone, 100 mg, as recommended by the manufacturer. All patients also received daily applications of 5 to 20 g of clobetasol propionate and methylprednisolone mouthwashes (20 mg 2 or 3 times a day) followed by a progressive withdrawal of treatment within a few weeks after significant improvement. The mean time after the first infusion to achieve complete (n = 4) or nearly complete (n = 1) healing of the disease (ie, absence or near absence of active lesions according to a Physician's Global Assessment [PGA] score of 0 or 1) was 15 weeks (range, 12-20 weeks). A dramatic decrease of the circulating desmoglein autoantibodies identified by indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA) was observed in all cases during remission. The median follow-up was 63 months (range, 42-78 months). Two patients did not experience relapse during 42 and 48 months of follow-up. Three patients experienced several relapses, with a mean time to the first relapse of 16 months after the first cycle of rituximab. Relapses were successfully treated with rituximab and topical corticosteroids, with follow-up evaluations at 1, 3, and 12 months since the last infusion (Table) . No adverse effects related to rituximab occurred during the study period, and no diabetes mellitus induced or worsened by topical corticosteroids was described. ranted for treatment of pemphigus vulgaris. As shown in several trials and many case reports and series, 4,6 rituximab has emerged as the most effective treatment for pemphigus vulgaris in refractory cases. Hematologic and rheumatologic regimens have similar effectiveness in autoimmune diseases, including pemphigus vulgaris. 8 However, the efficacy of rituximab as first-line treatment remains to be evaluated. A French prospective, randomized trial is being conducted to compare 2 first-line strategies for the treatment of pemphigus vulgaris: the classic high doses of corticosteroids alone vs lower doses and shorter durations of corticosteroids combined with rituximab (clinic altrials.gov identifier: NCT00784589), but the efficacy of rituximab without concomitant systemic corticosteroids has not been assessed. We report herein a series of 5 patients with pemphigus vulgaris of moderate severity successfully treated with a combination of rituximab and high-potency topical corticosteroids as first-line therapy without use of systemic corticosteroids because of various comorbidities. In a study conducted by Joly et al, 4 5 of 21 patients received rituximab without corticosteroids because of contraindications, and 4 of 5 were in complete remission at 3 months, as were the 16 patients receiving corticosteroids.
During the time to the initiation of the healing effects of rituximab in our patients with mild pemphigus vulgaris, we used short-term topical corticosteroids to limit the extension of the lesions and promote healing. Topical corticosteroid use has not been assessed in a blinded manner in the treatment of pemphigus vulgaris, in contrast with bullous pemphigoid, 9 but may be considered in very mild disease with low levels of autoantibodies. 10 In France, topical corticosteroids are available at a low cost (10 g of clobetasol propionate costs €2.28 [US $2.95] and 20 tablets of prednisolone for mouthwashes costs €4.88 [US $6.32]) and are reimbursed at 65% through Social Security. In 4 of our patients, the lesions began to heal 1 to 5 weeks after the first infusion and were in complete remission within 3 to 4 months. This time to achieve complete remission is similar to that in previously published studies with rituximab 4 and to the time to heal observed with systemic corticosteroids with or without mycophenolate mofetil. 11 Systemic circulation of topical corticosteroids and methylprednisolone infusion given as premedication could have played a role in the improvement of our patients, but that improvement probably was a minor and short-term effect. Indirect immunofluorescence showed a dramatic decrease of circulating antibodies in complete remission, with negative results in 4 patients and a low titer (1:160) in the patient who had the highest titer at diagnosis. In contrast, as previously shown, the results of antidesmoglein ELISA did not always parallel the clinical status, with a persistence of positive ELISA results (especially antidesmoglein 3 ELISA) in clinical remission in 3 patients. In our series, the patients' tolerance of rituximab was excellent and no severe treatment-related adverse effects occurred, even in the 3 patients in their 70s. We did not observe any topical corticosteroid-related diabetes mellitus. This outcome is in accordance with the good safety profile of rituximab reported 4,12 in pemphigus vulgaris, with an incidence of less than 10% of severe adverse effects. However, a significantly higher rate of rituximab-related mortality was recently described 13 in patients with autoimmune blistering diseases compared with patients with other autoimmune diseases (10.4% vs 2.4%), especially in patients receiving systemic corticosteroids, other immunosuppressive agents, or both given with rituximab. Furthermore, some unexpected cases of progressive, multifocal leukoencephalopathy and Pneumocystis jiroveci pneumonia have been described 14,15 in patients with autoimmune diseases. In our series, 3 of 5 patients experienced relapses, with a mean time for the first relapse of 16 months after the first cycle of rituximab. Our results are similar to those of previously published studies 4,12 reporting a rate of relapse of 40% to 60% and a median relapse-free remission of 19 months. A limitation to our study could be the lack of systematic monitoring of circulating CD19-positive B-cell levels during the treatment, especially in cases of relapse.
Conclusions
Concomitant use of rituximab and high-potency topical corticosteroids could be considered as treatment for pemphigus vulgaris in some patients with contraindications to use of high doses of systemic corticosteroids. However, larger long-term studies are needed to evaluate the optimal strategies according to the benefit-risk ratio of rituximab and the severity of the disease. Such studies are especially needed to evaluate which patients could benefit from rituximab without systemic corticosteroids and which ones would need short-term systemic corticosteroids to obtain the most rapid healing possible and thus reduce the risk of infectious complications. 
NOTABLE NOTES

Dangerous Plants of the Southwestern United States
Walter H. C. Burgdorf, MD; Leonard J. Hoenig, MD; R. Steven Padilla, MD, MBA
The Southwestern United States features a tricultural population (ie, Native Americans, descendants of early Spanish settlers, and Anglos), pleasant climate, and spectacular scenery ranging from mountains to deserts. While everyone is aware of rattlesnakes and scorpions as dangerous desert denizens, several desert plants also can be hazardous. Every Western movie fan knows what tumbleweeds are. While many plants disperse by drying and being blown along the ground, the best known one is Russian thistle (Kali tragus), which was introduced to the United States from Russia admixed with flax seeds in the 1870s. Tumbleweeds, when young, are edible. In the fall, they dry out and start their rolling journey, dispersing seeds as they go.
When humans handle tumbleweeds, they frequently get an irritant dermatitis. Injured persons may be gardeners, ranchers, or even handicrafters who build tumbleweed snowmen, piling the weeds together and then spray painting them white. Contact causes a distinctive and easily recognized clinical pattern-highly pruritic erythematous papules on the forearms. Treatment is symptomatic with topical corticosteroids or antipruritic agents. Powell and Smith 1 identified spiny bracts (modified leaves associated with flowers) as the main culprit. After testing 13 individuals, they suggested that there was a type I allergic component to the reaction, which can be more severe in sensitized individuals, such as those with allergic rhinitis from tumbleweed pollen. There are thousands of cacti, and no one needs to be told to avoid their long spines, which can cause significant traumatic injury.
2 But the chollas (Cylindropuntia) and prickly pears (Opuntia) of the US deserts have a more refined weaponry. They have areoles featuring both spines and glochids, which are short-barbed bristles. Slight contact results in the glochids being introduced into the skin, where they are capable of eliciting a granulomatous response. Often, the injured person is happy to have avoided the spines and initially scarcely notices the contact with the glochids, which later cause an inflammatory reaction, producing grouped 2-to 4-mm papules with a central dark punctum. Schreiber et al 3 studied 9 patients with cactus granulomas and suggested a possible type I allergic response based on positive results from intradermal skin tests. They also dramatically illustrated the tiny glochid barbs within macrophages in granulomas. While larger spines can be removed with tweezers or glue stripping, the glochids are too small to remove. Symptoms generally resolve in 10 to 14 days. When they do not, treatment with intralesional or high-potency topical corticosteroids are the best approach. Both immunologic studies 1, 3 were done in the 1970s; modern immunological techniques have not been applied to better understand the interplay between traumatic injury, the innate immune response, and sensitization of victims. But the clinical problems remain; be careful when handling tumbleweeds or certain cacti.
